Esperion Therapeutics, Inc. (ESPR)

1,9700 -0,0200 (-1,01%) Börsenschluss: 04:00PM EDT

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 240

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Sheldon L. Koenig	President, CEO & Director	1,28M	N/A	1966
Dr. JoAnne Micale Foody FACC, M.D.	Chief Medical Officer	856,87k	N/A	1965
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer	718,86k	N/A	1972
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer	N/A	N/A	1986
Mr. Glenn P. Brame	Chief Technical Operations Officer	N/A	N/A	1958
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary	550,35k	N/A	1982
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications	N/A	N/A	N/A
Ms. Betty Jean Swartz	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Esperion Therapeutics, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 3, Vorstand: 5, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.